Skip to Content
Søk Menu

Sara Tolaney

Sara Tolaney, MD, MPH, Chief, Division of Breast Oncology, Dana-Farber Cancer Institute, Boston, USA

MEDtalks

Sara Tolaney

ASCO 2025: Redefining First-Line Therapy in HER2+ Breast Cancer with T-DXd and Pertuzumab

/ Sara Tolaney
ASCO25BrystkreftNBCN Play the Video
Back to top